Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Teva Takeda Plans to Roll Out One AG Annually: CEO
April 11, 2019
- Kyowa to Skip May Listing for Enbrel Biosimilar, Codeveloper YL Biologics to Move Ahead
April 11, 2019
- Nearly 300 Kyowa Kirin Staffers Offer to Leave under Redundancy Program
April 11, 2019
- Hisamitsu Sales Down 3.4% on Price Cuts, Generic Erosion
April 11, 2019
- Diabetes Drug Imeglimin Hits Primary Goal in Japan PIII: Sumitomo, Poxel
April 10, 2019
- Xofluza Most Promoted Drug in January: Anterio
April 10, 2019
- Drug Makers Scratching Heads to Meet Daily Rep Report Requirements for New Detailing Guidelines
April 10, 2019
- Medipal’s Subsidiary to Distribute Stemirac in Japan
April 9, 2019
- Oncolys, Chugai Ink 50 Billion Yen Licensing Pact for Telomelysin
April 9, 2019
- Lixiana Waging Hand-to-Hand Combat with Xarelto in DOAC Market: Encise FY2018 Snapshot
April 8, 2019
- Novartis’ Eylea Challenger Could Reach Filing This Year for 2020 Launch
April 8, 2019
- 5 Industry-Academia Partners Tie Up for Research to Commercialize Renal Regenerative Medicine
April 8, 2019
- Japan Ethical Drug Sales Up 0.2% in February: Crecon
April 8, 2019
- FDA Accepts NDA Resubmission for Parkinson’s Drug Istradefylline: Kyowa Kirin
April 8, 2019
- Janssen Files Darzalex for Combination Therapy for Treatment-Naïve Multiple Myeloma in Japan
April 8, 2019
- FDA Extends Quizartinib Review by 3 Months: Daiichi Sankyo
April 5, 2019
- Cancer Drug Pexidartinib Filed in Europe: Daiichi Sankyo
April 5, 2019
- Clinigen Gets Japan Rights to Intracerebroventricular Form of Hunter Syndrome Drug Idursulfase Beta
April 5, 2019
- Lilly Japan Nets 263 Billion Yen in 2018, Now 6th in Sales Ranking
April 4, 2019
- Cefazolin Generic Shortage Raises Worries of Supply Crunch after G1 LLP Withdrawals
April 4, 2019
ページ
Chugai Pharmaceutical’s Duchenne muscular dystrophy (DMD) gene therapy Elevidys has finally reached the Japanese market after months of safety reviews…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…